Hatch Medical To Broker Chronic Total Occlusion Device

Main Category: Medical Devices / Diagnostics
Article Date: 03 Mar 2008 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced that it has recently entered into an agreement with Medical Miracles (Leeds, UK) to broker its patented and CE Marked chronic total occlusion (CTO) device, POLAR™.

POLAR™ (Path Of Least Arterial Resistance) is a mechanical device that generates reciprocal and lateral movements at the distal end of standard guidewires with frequencies of 16 to 100 Hz. when passed through an angioplasty balloon catheter, allowing clinicians to confidently cross occluded vessels.

Percutaneous interventions (PI) of a CTO remains one of the more difficult technical challenges for interventional practitioners, despite the progress made in the field of PI in the past decade. It has been estimated that CTOs are found in one-third of patients with significant vascular disease. Failure to revascularize a CTO often leaves the patient with either the more invasive option of bypass graft surgery or continuing medical therapy, which may or may not control their symptoms; neither is optimal.

In several published clinical studies which utilize the POLAR™ device in a technique known as "vibrational angioplasty", the device has proven to be both expedient and efficacious. In one such study, seventy-eight patients with chronic total occlusions (>3 months) that were resistant to conventional techniques were treated with the POLAR™ device using a variety of standard guidewires. The study found that lesions were successfully crossed in 67 (85.9%) of these cases and antegrade flow was re-established in 59 (75.5%) patients, causing one of the study participants to conclude, "The outcomes with this low-cost device have been favorable."

"We are pleased to be working with Medical Miracles' POLAR™ device and believe that it provides an efficacious and cost-effective solution to this chronic clinical challenge," commented Paul Gianneschi, Managing Principal of Hatch Medical, L.L.C.

Barry Kaye, CEO of Medical Miracles added, "We are excited to be working with Hatch Medical, as they have a long-standing history of successfully representing companies through the license or sale of complex medical technologies."

The POLAR™ device is available for licensing or acquisition to interested third parties through an exclusive agreement with Hatch Medical.

Hatch Medical

Article adapted by Medical News Today from original press release.
Visit our medical devices / diagnostics section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Hatch Medical. "Hatch Medical To Broker Chronic Total Occlusion Device." Medical News Today. MediLexicon, Intl., 3 Mar. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/99232.php>

APA
Hatch Medical. (2008, March 3). "Hatch Medical To Broker Chronic Total Occlusion Device." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/99232.php.

Please note: If no author information is provided, the source is cited instead.


Medical Devices / Diagnostics

Most Popular Articles



Follow Our Medical Devices News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Medical Devices / Diagnostics Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »